CN112898423B

CN112898423B - Binding protein for detecting CYFRA21-1 and detection method of CYFRA21-1

Info

Publication number: CN112898423B
Application number: CN201911227353.4A
Authority: CN
Inventors: 崔鹏; 何志强; 孟媛; 钟冬梅; 马秋燕; 梁碧; 游辉
Original assignee: Dongguan Pengzhi Biotechnology Co Ltd
Current assignee: Dongguan Pengzhi Biotechnology Co Ltd
Priority date: 2019-12-04
Filing date: 2019-12-04
Publication date: 2022-12-23
Anticipated expiration: 2039-12-04
Also published as: CN112898423A

Abstract

The invention discloses a binding protein for detecting CYFRA21-1 and a detection method for detecting CYFRA21-1, relating to the technical field of antibodies. The binding protein disclosed by the invention can be specifically bound with CYFRA21-1, has better binding activity and affinity, can be used for detecting CYFRA21-1 and can also be used for assisting in diagnosing tumors taking CYFRA21-1 as a marker, and the invention provides more protein selections for detecting CYFRA21-1 and diagnosing related tumors.

Description

Binding protein for detecting CYFRA21-1 and detection method of CYFRA21-1

Technical Field

The invention relates to the technical field of antibodies, in particular to a binding protein for detecting CYFRA21-1 and a detection method for detecting CYFRA21-1.

Background

Cytokeratin (CYK) is the intermediate filament of the cell body, is the major structural protein forming the epithelial cytoskeleton, and has the function of maintaining the integrity of epithelial cells. According to the difference of isoelectric point and molecular weight, CYK can be divided into type I and type II, wherein type I belongs to acidic protein, including CYK-9-CYK-23, type II belongs to basic protein, including CYK-1-CYK-8. Cytokeratin 19 is a class I acidic protein with a molecular weight of about 40KD, the smallest protein in the keratin family. It is widely distributed on normal tissue surface, such as stratified epithelium and squamous epithelium, and single-layer epithelial cells, such as acinus, sweat gland, mammary duct, trachea, endometrium, colon and hepatic cell. Soluble fragments of cytokeratin 19 bind specifically to two monoclonal antibodies KS19-1 and BM19-21 and are therefore designated CYFRA21-1. Cytokeratin 19 is normally not expressed or is low expressed in peripheral blood, bone marrow, lymph nodes. In malignant epithelial tumors, the activated proteases accelerate cellular degradation, causing the release of large amounts of soluble cytokeratin 19 fragments, resulting in an increase in the concentration of soluble cytokeratin 19 fragments in blood, tissue fluids, body fluids.

Lung cancer is one of the most common malignant tumors all over the world at present, and the incidence rate of lung cancer is continuously increased with the aggravation of urban pollution in China in recent years. The lung cancer is divided into two major categories, namely small cell lung cancer and non-small cell lung cancer, early symptoms of the lung cancer are not obvious, and the survival rate of lung cancer patients is reduced because most patients are diagnosed in a non-early stage due to low histopathology, imaging and cytological sensitivity. If the lung cancer can be found on the tumor serum marker, clinical early intervention is carried out, and the method has very important significance for improving the cure rate and survival rate of lung cancer patients.

In recent years, scientists have actively studied tumor markers. In the history of the discovery of cytokeratin 19 fragments, bodenmuller et al first used two monoclonals (BMl 9-21 and KSl9.1) to detect cytokeratin 19 fragments in serum in 1992. Stieber et al, 1993, reported clinical significance in detecting cytokeratin 19 fragments in the serum of patients with lung cancer. In 1998, the concentration threshold of the cytokeratin 19 fragment in the serum of a lung cancer patient is determined by Borui et al, which shows that the cytokeratin 19 fragment is a good index for monitoring the lung cancer and prompting the curative effect, is a good tumor marker of the non-small cell lung cancer, is particularly suitable for the lung squamous cancer, but has limited effect on early diagnosis of the non-small cell lung cancer. In subsequent researches, CYFRA21-1 is found to be a preferred marker of non-small cell lung cancer, in particular to a specific standard of lung squamous cell carcinoma. Recent researches find that the combined detection of CYFRA21-1, CEA and NSE has insufficient diagnosis and complementation on lung cancer, improves specificity and positive rate, and provides basis for clinical early diagnosis and treatment.

Clinically, the normal value in CYFRA21-1 serum is less than 3.5 mug/l, is a good index for monitoring the lung cancer and prompting the curative effect, has higher sensitivity and specificity to the non-small cell lung cancer, and is a preferred marker for detecting the non-small cell lung cancer. The elevation of CYFRA21-1 is not caused by pneumonia, pulmonary tuberculosis, bronchitis, bronchial asthma, emphysema and other diseases. Also can be combined with other tumor markers to detect invasive bladder cancer, breast, cervical and digestive tract tumors, etc.

At present, the monoclonal antibody for detecting CYFRA21-1 in China has some defects in sensitivity, specificity and affinity and has larger space for improvement, so that the field still has strong demand for the monoclonal antibody for detecting CYFRA21-1.

Disclosure of Invention

The invention aims to provide a binding protein for detecting CYFRA21-1 and a detection method for detecting CYFRA21-1. The binding protein provided by the invention can specifically bind to CYFRA21-1, has better binding activity and affinity, can be used for detecting CYFRA21-1, can also be used for assisting in diagnosing tumors taking CYFRA21-1 as a marker, and provides more protein selections for detecting CYFRA21-1 and diagnosing related tumors.

Noun definitions

The term "binding protein" broadly refers to all proteins/protein fragments, in particular antibodies or functional fragments of antibodies, comprising CDR regions. The term "antibody" includes polyclonal and monoclonal antibodies, and "antibody functional fragments" include antigen-compound-binding fragments of these antibodies, including Fab, F (ab') 2, fd, fv, scFv, diabodies, and minimal recognition units, as well as single chain derivatives of these antibodies and fragments. The type of antibody can be selected from IgG1, igG2, igG3, igG4, igA, igM, igE, and IgD. Furthermore, the term "antibody" includes naturally occurring antibodies as well as non-naturally occurring antibodies, including, for example, chimeric (chimeric), bifunctional (bifunctional) and humanized (humanized) antibodies, as well as related synthetic isomeric forms (isoforms). The term "antibody" is used interchangeably with "immunoglobulin".

The "variable region" or "variable domain" of an antibody refers to the amino-terminal domain of the heavy or light chain of the antibody. The variable domain of the heavy chain may be referred to as "VH". The variable domain of the light chain may be referred to as "VL". These domains are usually the most variable parts of an antibody and contain an antigen binding site. The light or heavy chain variable region (VL or VH) is composed of framework regions interrupted by three hypervariable regions, termed "complementarity determining regions" or "CDRs". The extent of the framework regions and CDRs has been precisely defined, for example, in Kabat (see Sequences of Proteins of Immunological Interest), E.Kabat et al, U.S. department of Health and Human Services (U.S.. Department of Health and Human Services), (1983), and Chothia. The framework regions of the antibody, which constitute the combination of the essential light and heavy chains, serve to locate and align the CDRs, which are primarily responsible for binding to the antigen.

As used herein, "framework region" or "FR" region means the region of an antibody variable domain excluding those defined as CDRs. Each antibody variable domain framework can be further subdivided into adjacent regions (FR 1, FR2, FR3 and FR 4) separated by CDRs.

In general, the variable domains VL/VH of the heavy and light chains can be obtained by linking the CDRs and FRs, numbered as follows, in a combined arrangement: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.

As used herein, the term "purified" or "isolated" in relation to a polypeptide or nucleic acid means that the polypeptide or nucleic acid is not in its native medium or native form. Thus, the term "isolated" includes a polypeptide or nucleic acid that is removed from its original environment, e.g., from its natural environment if it is naturally occurring. For example, an isolated polypeptide is generally free of at least some proteins or other cellular components that are normally bound to or normally mixed with it or in solution. Isolated polypeptides include naturally-produced such polypeptides contained in cell lysates, in purified or partially purified form, recombinant polypeptides, such polypeptides expressed or secreted by cells, and such polypeptides in heterologous host cells or cultures. In connection with a nucleic acid, the terms "isolated" or "purified" mean that the nucleic acid is not in its natural genomic context (e.g., in a vector, as an expression cassette, linked to a promoter, or artificially introduced into a heterologous host cell).

Exemplary embodiments of the invention:

in a first aspect, embodiments of the present invention provide a binding protein for detecting CYFRA21-1, the binding protein comprising an antigen binding domain; the antigen binding domain comprises at least one of the following complementarity determining regions, or a similar complementarity determining region having at least 80% sequence identity to the sequence of at least one of the following complementarity determining regions:

a complementarity determining region CDR-VH1 having an amino acid sequence of G-F-X1-F-S-X2-Y-W-M-N, wherein: x1 is S or T, X2 is Q, N or K;

a complementarity determining region CDR-VH2 having an amino acid sequence of E-X1-T-L-K-S-X2-N-Y-X3-X4-H-Y-A-E-S-V-K-G, wherein: x1 is I, V or L, X2 is D or N, X3 is I, V or A, X4 is I, A or L;

Sub>A complementarity determining region CDR-VH3 having an amino acid sequence of T-X1-F-Sub>A-M-X2-Y, wherein: x1 is Q, R, H or K, X2 is E or D;

a complementarity determining region CDR-VL1 having the amino acid sequence R-A-S-Q-X1-X2-R-X3-N-X4-D, wherein: x1 is N, D or E, X2 is I or L, X3 is S or G, X4 is I or L;

a complementarity determining region CDR-VL2 having an amino acid sequence S-X1-S-N-X2-X3-S, wherein: x1 is T or S, X2 is I or L, X3 is N or D;

a complementarity determining region CDR-VL3 having the amino acid sequence X1-Q-R-X2-A-Y-P-X3-T, wherein: x1 is I or L, X2 is N, D or A, and X3 is I or L.

The binding protein provided by the embodiment of the invention contains an antigen binding domain, the antigen binding domain comprises at least one of the complementarity determining regions, the amino acid sequence of the complementarity determining region is found and disclosed for the first time in the invention, the binding protein is a novel sequence, the binding protein can be endowed with the capability of specifically binding to CYFRA21-1 antigen, the binding protein has better binding activity and affinity, the sensitivity and specificity of detection can be improved by using the binding protein to detect CYFRA21-1, the binding protein can be used for diagnosing tumors using CYFRA21-1 as a marker, and the invention provides more protein selections for the detection of CYFRA21-1 and the diagnosis or auxiliary diagnosis of tumors using CYFRA21-1 as a marker.

In alternative embodiments, in the complementarity determining region CDR-VH1, X1 is T; in the complementarity determining region CDR-VH2, X1 is I; in the complementarity determining region CDR-VH3, X2 is D; in the complementarity determining region CDR-VL1, X3 is G; in the complementarity determining region CDR-VL2, X1 is T; in the CDR-VL3, X1 is L.

In alternative embodiments, in the complementarity determining region CDR-VH1, X2 is Q.

In alternative embodiments, in the complementarity determining region CDR-VH1, X2 is N.

In an alternative embodiment, in the complementarity determining region CDR-VH1, X2 is K.

In alternative embodiments, in the complementarity determining region CDR-VH2, X2 is D.

In alternative embodiments, in the complementarity determining region CDR-VH2, X2 is N.

In alternative embodiments, in the complementarity determining region CDR-VH2, X3 is I.

In an alternative embodiment, in the complementarity determining region CDR-VH2, X3 is V.

In alternative embodiments, in the complementarity determining region CDR-VH2, X3 is a.

In alternative embodiments, in the complementarity determining region CDR-VH2, X4 is I.

In alternative embodiments, in the complementarity determining region CDR-VH2, X4 is a.

In alternative embodiments, in the complementarity determining region CDR-VH2, X4 is L.

In an alternative embodiment, in the complementarity determining region CDR-VH3, X1 is Q.

In an alternative embodiment, in the complementarity determining region CDR-VH3, X1 is R.

In alternative embodiments, in the complementarity determining region CDR-VH3, X1 is H.

In an alternative embodiment, in the complementarity determining region CDR-VH3, X1 is K.

In alternative embodiments, in the complementarity determining region CDR-VL1, X1 is N.

In an alternative embodiment, in the complementarity determining region CDR-VL1, X1 is D.

In an alternative embodiment, in the complementarity determining region CDR-VL1, X1 is E.

In alternative embodiments, in the complementarity determining region CDR-VL1, X2 is I.

In an alternative embodiment, in the complementarity determining region CDR-VL1, X2 is L.

In alternative embodiments, in the complementarity determining region CDR-VL1, X4 is I.

In alternative embodiments, in the complementarity determining region CDR-VL1, X4 is L.

In an alternative embodiment, in the complementarity determining region CDR-VL2, X2 is I.

In alternative embodiments, in the complementarity determining region CDR-VL2, X2 is L.

In alternative embodiments, in the complementarity determining region CDR-VL2, X3 is N.

In alternative embodiments, in the complementarity determining region CDR-VL2, X3 is D.

In alternative embodiments, in the complementarity determining region CDR-VL3, X2 is N.

In alternative embodiments, in the complementarity determining region CDR-VL3, X2 is D.

In alternative embodiments, in the complementarity determining region CDR-VL3, X2 is a.

In alternative embodiments, in the complementarity determining region CDR-VL3, X3 is I.

In alternative embodiments, in the complementarity determining region CDR-VL3, X3 is L.

In alternative embodiments, the similar complementarity determining regions have at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequences of the complementarity determining regions described above.

In alternative embodiments, the antigen binding domain has K with CYFRA21-1 protein _D ≤6.45×10 ^- ⁸ Affinity of mol/L;

in alternative embodiments, the antigen binding domain has K with CYFRA21-1 protein _D ≤6×10 ^- ⁸ mol/L、5×10 ^-8 mol/L、4×10 ^-8 mol/L、3×10 ^-8 mol/L、2×10 ^-8 mol/L、1×10 ^-8 mol/L、9×10 ^- ⁹ mol/L、8×10 ^-9 mol/L、7×10 ^-9 mol/L、6×10 ^-9 mol/L、5×10 ^-9 mol/L、4×10 ^-9 mol/L、3×10 ^- ⁹ mol/L、2×10 ^-9 mol/L、1×10 ^-9 mol/L、9×10 ^-10 mol/L、8×10 ^-10 mol/L、7×10 ^-10 mol/L、6×10 ^- ¹⁰ mol/L、5×10 ^-10 mol/L or 4X 10 ^-10 Affinity of mol/L;

in an alternative embodiment, the antigen binding domain has a 4.89 x 10 affinity for CYFRA21-1 protein ^-10 ≤K _D ≤6.45×10 ^-8 Affinity of mol/L.

K _D The detection of (2) is carried out with reference to the method in the examples of the present invention.

In an alternative embodiment, the mutation site (i.e., xn site, n =1,2,3 or 4) in each of the complementarity determining regions described above is selected from any one of the following combinations of mutations 1-58:

in alternative embodiments, in the complementarity determining region CDR-VH1, X1 is S; in the CDR-VH2, X1 is L; in the CDR-VH3, X2 is E; in the complementarity determining region CDR-VL1, X3 is S; in the complementarity determining region CDR-VL2, X1 is S; in the CDR-VL3, X1 is I.

In alternative embodiments, the mutation site (i.e., xn site, n =1,2,3 or 4) in each of the complementarity determining regions described above is selected from any one of the following combinations of mutations 59-66:

in alternative embodiments, the binding protein includes at least 3 complementarity determining regions (e.g., 3 complementarity determining regions of a heavy chain, or3 complementarity determining regions of a light chain); alternatively, the binding protein comprises at least 6 complementarity determining regions (e.g., 3 complementarity determining regions of a heavy chain and 3 complementarity determining regions of a light chain);

in alternative embodiments, the binding protein is a whole antibody comprising a variable region and a constant region.

In alternative embodiments, the binding protein is a functional fragment of an antibody, such as any one of a nanobody, F (ab ') 2, fab', fab, fv, scFv, diabody, and antibody minimal recognition unit;

functional fragments of the above antibodies typically have the same binding specificity as the antibody from which they are derived. As will be readily understood by those skilled in the art based on the teachings of the present invention, functional fragments of the above antibodies can be obtained by methods such as enzymatic digestion (including pepsin or papain) and/or by chemical reduction to cleave disulfide bonds.

Functional fragments of the above antibodies can also be obtained by recombinant genetic techniques also known to those skilled in the art or synthesized by, for example, an automated peptide synthesizer, such as those sold by Applied BioSystems and the like.

In alternative embodiments, the binding protein comprises light chain framework regions FR-L1, FR-L2, FR-L3 and FR-L4, as set forth in sequence in SEQ ID NOS 1-4, and/or heavy chain framework regions FR-H1, FR-H2, FR-H3 and FR-H4, as set forth in sequence in SEQ ID NOS 5-8.

Based on the present disclosure, the species of the heavy or light chain framework region of the binding protein may be human to form a humanized antibody.

In alternative embodiments, the binding protein further comprises an antibody constant region.

In alternative embodiments, the antibody constant region is selected from the constant regions of any one of IgG1, igG2, igG3, igG4, igA, igM, igE and IgD.

In alternative embodiments, the species of the antibody constant region is from a cow, horse, dairy cow, pig, sheep, goat, rat, mouse, dog, cat, rabbit, camel, donkey, deer, mink, chicken, duck, goose, turkey, chicken fountains, or human.

In alternative embodiments, the antibody constant region is derived from a mouse.

In alternative embodiments, the light chain constant region sequence of the antibody constant region is set forth in SEQ ID NO. 9 and the heavy chain constant region sequence of the antibody constant region is set forth in SEQ ID NO. 10.

The sequences of SEQ ID NOS: 1-10 are shown in the following table:

in a second aspect, the embodiments provide the use of a binding protein according to any one of the preceding embodiments in the preparation of a tumour-associated diagnostic reagent or kit, wherein the tumour marker comprises CYFRA21-1 protein.

In an alternative embodiment, the tumor is selected from any one of lung cancer, bladder cancer, breast cancer, cervical cancer and digestive tract tumor.

In alternative embodiments, the tumor is lung cancer.

In alternative embodiments, the lung cancer is non-small cell lung cancer.

In an alternative embodiment, the non-small cell lung cancer is selected from any one of squamous lung cancer, adenocarcinoma of lung, poorly differentiated lung cancer and large cell lung cancer.

In an alternative embodiment, the test sample of the reagent or kit is serum.

In a third aspect, the embodiments of the present invention provide a tumor auxiliary diagnostic reagent or kit, wherein the tumor marker comprises CYFRA21-1 protein containing the binding protein as described above.

In alternative embodiments, the tumor is lung cancer.

In alternative embodiments, the lung cancer is non-small cell lung cancer.

In an alternative embodiment, the test sample of the reagent or kit is serum.

In a fourth aspect, embodiments of the present invention provide a method for detecting CYFRA21-1, comprising: mixing a binding protein according to any one of the preceding embodiments with a sample to be tested.

In an alternative embodiment, the above method is for the purpose of non-disease diagnosis.

It should be noted that, the skilled person can qualitatively or quantitatively detect the CYFRA21-1 protein in the test sample based on the characteristics of the immune complex formed by the antibody/antigen combination. The method for detecting an antigen or an antibody based on the formation of an immune complex upon binding of the antibody to the antigen comprises:

(1) The detection purpose is realized by a precipitation reaction, which comprises the following steps: a one-way immunodiffusion test, a two-way immunodiffusion test, an immunoturbidimetry, a convective immunoelectrophoresis, an immunoblotting method, and the like;

(2) The detection purpose is realized by marking an indicator for displaying the signal intensity, and the method comprises the following steps: immunofluorescence, radioimmunoassay, enzyme-linked immunoassay (e.g., double antibody sandwich, indirect or competitive assay), and chemiluminescence immunoassay.

The indicator may be appropriately selected according to various detection methods, including but not limited to the indicators described below:

(1) In immunofluorescence, the indicator may be a fluorescent dye, for example, a fluorescein-based dye (including isothiocyanate, \33440 (FIIC), hydroxyphotoxin (FAM), tetrachlorofluorescein (TET), etc., or an analog thereof), a rhodamine-based dye (including red Rhodamine (RBITC), tetramethylrhodamine (TAMRA), rhodamine B (TRITC), etc., or an analog thereof), a Cy-series dye (including Cy2, cy3B, cy3.5, cy5, cy5.5, cy3, etc., or an analog thereof), an Alexa-series dye (including Alexa fluor350, 405, 430, 532, 546, 568, 594, 610, 33, 647, 680, 700, 750, etc., or an analog thereof), a protein-based dye (including Phycoerythrin (PE), phycocyanin (PC), allophycocyanin (allophycocyanin), polymetaxanthin-chlorophyll protein (preCP), etc.;

(2) In radioimmunoassays, the indicator may be a radioisotope, for example: 212Bi, 131I, 111In, 90Y, 186Re, 211At, 125I, 188Re, 153Sm, 213Bi, 32P, 94mTc, 99mTc, 203Pb, 67Ga, 68Ga, 43Sc, 47Sc, 110mIn, 97Ru, 62Cu, 64Cu, 67Cu, 68Cu, 86Y, 88Y, 121Sn, 161Tb, 166Ho, 105Rh, 177Lu, 172Lu, and 18F, and the like.

(3) In enzyme-linked immunoassays, the indicator may be an enzyme that catalyzes the development of a substrate (e.g., horseradish peroxidase, alkaline phosphatase, or glucose oxidase, etc.).

(4) In chemiluminescent immunoassays, the indicator may be a chemiluminescent reagent such as acridinium ester, horseradish peroxidase and luminol, alkaline phosphatase and AMPPD, electrochemiluminescent agents ruthenium and tripropylamine, and the like.

Based on the disclosure of the above binding protein, those skilled in the art can easily think of using any one or a combination of several methods or other methods to achieve quantitative or qualitative detection of CYFRA21-1 in a test sample, and whatever method is selected, it is within the scope of the present invention to use the binding protein disclosed in the present invention to detect CYFRA21-1.

In an alternative embodiment, the binding protein is labeled with an indicator showing signal intensity such that the complex in which the binding protein binds to CYFRA21-1 protein is detected.

In a fifth aspect, embodiments provide an isolated nucleic acid encoding a binding protein according to any one of the preceding embodiments;

in alternative embodiments, the nucleic acid is DNA or RNA.

Based on the disclosure of the amino acid sequence of the binding protein, one skilled in the art can easily obtain the nucleic acid sequence encoding the binding protein according to the codon corresponding to the amino acid, and obtain various nucleic acid sequences encoding the binding protein according to the degeneracy of the codon, which are within the protection scope of the present invention as long as they encode the binding protein.

In a sixth aspect, the embodiments provide a vector comprising a nucleic acid according to the previous embodiments.

Wherein the nucleic acid sequence is operably linked to at least one regulatory sequence. "operably linked" refers to a nucleic acid sequence that is linked to a regulatory sequence in a manner that allows for expression. Regulatory sequences, including promoters, enhancers and other expression control elements, are selected to direct the expression of the protein of interest in a suitable host cell.

Herein, a vector may refer to a molecule or agent comprising a nucleic acid of the invention or a fragment thereof, capable of carrying genetic information and capable of delivering the genetic information into a cell. Typical vectors include plasmids, viruses, bacteriophages, cosmids, and minichromosomes. The vector may be a cloning vector (i.e. a vector for transferring genetic information into a cell, which cell may be propagated and in which the presence or absence of the genetic information may be selected) or an expression vector (i.e. a vector comprising the necessary genetic elements to allow expression of the genetic information of the vector in a cell). Thus, a cloning vector may contain a selectable marker, as well as an origin of replication compatible with the cell type specified by the cloning vector, while an expression vector contains the regulatory elements necessary to effect expression in a specified target cell.

The nucleic acids of the invention or fragments thereof may be inserted into a suitable vector to form a cloning or expression vector carrying the nucleic acid fragments of the invention. Such novel vectors are also part of the present invention. The vector may comprise a plasmid, phage, cosmid, minichromosome, or virus, as well as naked DNA that is transiently expressed only in a particular cell. The cloning and expression vectors of the present invention are capable of autonomous replication and therefore are capable of providing high copy numbers for high level expression or high level replication purposes for subsequent cloning. The expression vector may comprise a promoter for driving expression of the nucleic acid fragment of the invention, optionally a signal peptide sequence encoding for secretion or integration of the protein expression product into a membrane, and optionally a nucleic acid sequence encoding for a terminator. When the expression vector is manipulated in a production strain or cell line, the vector, when introduced into a host cell, may or may not be integrated into the genome of the host cell. Vectors typically carry a replication site, as well as a marker sequence capable of providing phenotypic selection in transformed cells.

In a seventh aspect, embodiments of the present invention provide a host cell comprising a vector according to the previous embodiments.

The expression vectors of the invention are useful for transforming host cells. Such transformed host cells are also part of the invention and may be cultured cells or cell lines for propagation of the nucleic acid fragments and vectors of the invention, or for recombinant production of the binding proteins of the invention. Host cells of the present invention include microorganisms such as bacteria (e.g., escherichia coli, bacillus, etc.). Host cells also include cells from multicellular organisms such as fungi, insect cells, plant cells or mammalian cells, preferably from mammals, e.g., CHO cells.

In an eighth aspect, embodiments of the invention provide a method of producing a binding protein of any one of the preceding embodiments, comprising:

the host cell of the previous embodiment is cultured, and the binding protein is isolated and purified from the culture medium or from the cultured host cell.

The production method may be, for example, transfecting a host cell with a nucleic acid vector encoding at least a portion of the binding protein, and culturing the host cell under suitable conditions such that the binding protein is expressed. The host cell may also be transfected with one or more expression vectors, which may comprise, alone or in combination, DNA encoding at least a portion of the binding protein. The bound protein may be isolated from the culture medium or cell lysate using conventional techniques for purifying proteins and peptides, including ammonium sulfate precipitation, chromatography (e.g., ion exchange, gel filtration, affinity chromatography, etc.), and/or electrophoresis.

Construction of suitable vectors containing the coding and regulatory sequences of interest can be carried out using standard ligation and restriction techniques well known in the art. The isolated plasmid, DNA sequence or synthetic oligonucleotide is cleaved, tailed and religated as desired. Any method may be used to introduce mutations into the coding sequence to produce variants of the invention, and these mutations may comprise deletions or insertions or substitutions or the like.

Drawings

In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the embodiments will be briefly described below, it should be understood that the following drawings only illustrate some embodiments of the present invention and therefore should not be considered as limiting the scope, and for those skilled in the art, other related drawings can be obtained according to the drawings without inventive efforts.

FIG. 1 is a reduced SDS-PAGE of the monoclonal antibody of CYFRA21-1 of example 1.

Detailed Description

In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. The examples, in which specific conditions are not specified, were carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the formulations or unit dosages herein, some are now described. Unless otherwise indicated, the techniques employed or contemplated herein are standard methods. The materials, methods, and examples are illustrative only and not intended to be limiting.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, molecular biology (including recombinant techniques), microbiology, biochemistry and immunology, which are within the skill of the art. Such techniques are well explained in the literature, e.g. "molecular cloning: a Laboratory Manual, second edition (Sambrook et al, 1989); oligonucleotide Synthesis (oligo Synthesis) (eds. M.j. Goal, 1984); animal Cell Culture (Animal Cell Culture), ed.r.i. freshney, 1987; methods in Enzymology (Methods in Enzymology), academic Press, inc. (Academic Press, inc.), "Handbook of Experimental Immunology" ("D.M.Weir and C.C.Black well"), gene Transfer Vectors for Mammalian Cells (J.M.Miller and M.P.Calos.), "Current Protocols in Molecular Biology" (F.M.Ausubel et al., 1987), "PCR, polymerase Chain Reaction (PCR: the Polymerase Chain Reaction) (Mullis et al., 1994), and" Current Protocols in Immunology "(blood), each of which is incorporated herein by reference, cold, 1991.

Several aspects of the invention are described below with reference to example applications for illustration. It should be understood that numerous specific details, relationships, and methods are set forth to provide a full understanding of the invention. One of ordinary skill in the relevant art will readily recognize, however, that the invention can be practiced without one or more of the specific details or with other methods. The present invention is not limited by the illustrated ordering of activities or events, as some activities may occur in different orders and/or concurrently with other activities or events. Moreover, not all illustrated acts or events are required to implement a methodology in accordance with the present invention.

The features and properties of the present invention are described in further detail below with reference to examples.

Example 1

Restriction enzyme, prime Star DNA polymerase, was purchased from Takara in this example. MagExtractor-RNA extraction kit was purchased from TOYOBO. BD SMART ^TM RACE cDNA Amplification Kit was purchased from Takara. pMD-18T vector was purchased from Takara. Plasmid extraction kits were purchased from Tiangen corporation. Primer synthesis and gene sequencing were performed by Invitrogen corporation.

This example provides a method for the preparation of recombinant antibodies against CYFRA21-1

1 construction of recombinant plasmid

(1) Primer and method for producing the same

Amplifying Heavy Chain and Light Chain 5' RACE primers:

(2) Antibody variable region gene cloning and sequencing

RNA is extracted from a hybridoma cell strain secreting a monoclonal antibody against CYFRA21-1, first strand cDNA synthesis is carried out by using a SMARTERTM RACE cDNA Amplification Kit and SMARTER II A Oligonucleotide and 5' -CDS primers in the Kit, and an obtained first strand cDNA product is used as a PCR Amplification template. The Light Chain gene was amplified with Universal Primer A Mix (UPM), nested Universal Primer A (NUP) and mIgG CKR primers, and the Heavy Chain gene was amplified with Universal Primer A Mix (UPM), nested Universal Primer A (NUP) and mIgG CHR primers. The primer pair of Light Chain can amplify a target band about 0.8KB, and the primer pair of Heavy Chain can amplify a target band about 1.4 KB. The product is added with A by rTaq DNA polymerase, inserted into pMD-18T vector, transformed into DH5 alpha competent cell, and cloned with Heavy Chain and Light Chain genes respectively after growing colony, and sent to Invitrogen company for sequencing.

(3) Sequence analysis of variable region Gene of anti-CYFRA 21-1 monoclonal antibody

Putting the gene sequence obtained by sequencing in an IMGT antibody database for analysis, and analyzing by using VNTI11.5 software to determine that the genes amplified by the heavy Chain primer pair and the Light Chain primer pair are correct, wherein in the gene fragment amplified by the Light Chain, the VL gene sequence is 324bp, belongs to VkII gene family, and a leader peptide sequence of 57bp is arranged in front of the VL gene sequence; in the gene fragment amplified by the Heavy Chain primer pair, the VH gene sequence is 348bp, belongs to a VH1 gene family, and has a leader peptide sequence of 57bp in front.

(4) Construction of recombinant antibody expression plasmid

pcDNA ^TM 3.4

vector is a constructed recombinant antibody eukaryotic expression vector, and multiple cloning enzyme cutting sites such as HindIII, bamHI, ecoRI and the like are introduced into the expression vector and named as pcDNA3.4A expression vector, and the vector is called as 3.4A expression vector for short in the following; according to the sequencing result of the antibody variable region gene in the pMD-18T, the light chain and heavy chain gene specific primers of the anti-CYFRA 21-1 antibody are designed, and the two ends are respectively provided with HindIII,EcoRI restriction site and protection base, the primers are as follows:

a0.75 KB Light Chain gene fragment and a 1.42KB Heavy Chain gene fragment were amplified by PCR amplification. The gene fragments of the Heavy Chain and the Light Chain are subjected to double enzyme digestion by HindIII/EcoRI respectively, the 3.4A vector is subjected to double enzyme digestion by HindIII/EcoRI, the gene of the Heavy Chain and the gene of the Light Chain are respectively connected into the 3.4A expression vector after the fragments and the vector are purified and recovered, and recombinant expression plasmids of the Heavy Chain and the Light Chain are respectively obtained.

2 Stable cell line selection

(1) Transient transfection of recombinant antibody expression plasmid into CHO cell, determination of expression plasmid activity

Plasmid was diluted to 400ng/ml with ultrapure water and CHO cells were conditioned at 1.43X 10 ⁷ cells/ml are put into a centrifuge tube, 100 mul of plasmid is mixed with 700 mul of cells, the mixture is transferred into an electric rotating cup and is electrically rotated, the sampling counting is carried out on 3 rd, 5 th and 7 th days, and the sampling detection is carried out on 7 th day.

Diluting the recombinant CYFRA21-1 protein (produced by oneself) to 1 mu g/ml by the coating solution, wherein each well is 100 mu l, and the temperature is 4 ℃ overnight; on the next day, washing with the washing solution for 2 times, and patting to dry; blocking solution (20% BSA +80% PBS) was added, 120. Mu.l per well, 37 ℃,1h, patted dry; adding diluted cell supernatant at 100 μ l/well, 37 deg.C for 30min (partial supernatant for 1 h); washing with the washing solution for 5 times, and drying; adding goat anti-mouse IgG-HRP (goat anti-mouse IgG-HRP) with the concentration of 100 mu l per well at 37 ℃ for 30min; washing with the washing solution for 5 times, and drying; adding a developing solution A (50 μ l/hole), adding a developing solution B (50 μ l/hole), and standing for 10min; adding stop solution into the mixture, wherein the concentration of the stop solution is 50 mu l/hole; OD readings were taken at 450nm (reference 630 nm) on the microplate reader. The results show that the reaction OD after the cell supernatant is diluted 1000 times is still greater than 1.0, and the reaction OD of the wells without the cell supernatant is less than 0.1, which indicates that the antibodies generated after the plasmid is transiently transformed are all active on the CYFRA21-1 protein.

(2) Linearization of recombinant antibody expression plasmids

The following reagents were prepared: 50 mul Buffer, 100 mu g DNA/tube, 10 mul PuvI enzyme and sterile water to 500 mul, and carrying out enzyme digestion in water bath at 37 ℃ overnight; extraction was performed sequentially with equal volumes of phenol/chloroform/isoamyl alcohol (lower layer) 25; precipitating with 0.1 times volume (water phase) of 3M sodium acetate and 2 times volume of ethanol on ice, rinsing with 70% ethanol, removing organic solvent, re-melting with appropriate amount of sterilized water after ethanol is completely volatilized, and finally measuring concentration.

(3) Stable transfection of recombinant antibody expression plasmid, pressurized screening of stable cell lines

Plasmid was diluted to 400ng/ml with ultrapure water and CHO cells were conditioned at 1.43X 10 ⁷ cells/ml are put into a centrifuge tube, 100 mul of plasmid is mixed with 700 mul of cells, and the mixture is transferred into an electric rotating cup and is electrically rotated, and the next day is counted; 25 u mol/L MSX 96 hole pressure culture about 25 days.

Observing the marked clone holes with cells under a microscope, and recording the confluence degree; taking culture supernatant, and sending the culture supernatant to a sample for detection; selecting cell strains with high antibody concentration and relative concentration, transferring the cell strains into 24 holes, and transferring the cell strains into 6 holes after 3 days; after 3 days, the seeds were kept and cultured in batches, and the cell density was adjusted to 0.5X 10 ⁶ cells/ml,2.2ml, cell density 0.3X 10 ⁶ cell/ml, 2ml for seed preservation; and (4) 7 days, carrying out batch culture supernatant sample detection in 6 holes, and selecting cell strains with small antibody concentration and cell diameter, transferring the cell strains to TPP (thermoplastic vulcanizate) for seed preservation and passage.

3 recombinant antibody production

(1) Cell expanding culture

After the cells were recovered, they were cultured in 125ml size shake flasks, inoculated with 30ml Dynamis medium at a culture medium volume of 100%, and placed in a shaker at a rotation speed of 120r/min and a temperature of 37 ℃ with 8% carbon dioxide. Culturing for 72h, inoculating and expanding at an inoculation density of 50 ten thousand cells/ml, the expanding volume being calculated according to the production requirements, the medium being 100% Dynamis medium. Then the culture is expanded every 72 h. When the cell amount meets the production requirement, the production is carried out by strictly controlling the inoculation density to be about 50 ten thousand cells/ml.

(2) Shake flask production and purification

Shake flask parameters: the rotating speed is 120r/min, the temperature is 37 ℃, and the carbon dioxide is 8 percent. Feeding in a flowing mode: daily feeding was started when the culture was carried out for 72h in a shake flask, 3% of the initial culture volume was fed daily to HyCloneTM Cell BoostTM Feed 7a, and one thousandth of the initial culture volume was fed daily to Feed 7b, up to day 12 (day 12 feeding). Glucose was supplemented with 3g/L on the sixth day. Samples were collected on day 13. Affinity purification was performed using a proteinA affinity column. Mu.g of the purified antibody (i.e., CYFRA21-1 monoclonal antibody) was subjected to reducing SDS-PAGE, and the electrophoretogram thereof was shown in FIG. 1. Two bands were shown after reducing SDS-PAGE, 1 with 50kD of Mr (i.e., heavy chain, SEQ ID NO: 14) and 28kD of Mr (i.e., light chain, SEQ ID NO: 12).

Example 2

Detection of antibody Performance

(1) Example 1 Activity assay of antibodies and mutants thereof

Further analysis revealed that the heavy chain variable region of the CYFRA21-1 monoclonal antibody (WT) of example 1 is shown in SEQ ID NO:13, wherein the amino acid sequences of the complementarity determining regions of the heavy chain are as follows:

CDR-VH1：G-F-S(X1)-F-S-Q(X2)-Y-W-M-N；

CDR-VH2：E-L(X1)-T-L-K-S-D(X2)-N-Y-I(X3)-A(X4)-H-Y-A-E-S-V-K-G；

CDR-VH3：T-H(X1)-F-A-M-E(X2)-Y；

the light chain variable region is shown as SEQ ID NO. 11, wherein the amino acid sequences of the complementarity determining regions of the light chain are as follows:

CDR-VL1：R-A-S-Q-N(X1)-I(X2)-R-S(X3)-N-I(X4)-D；

CDR-VL2：S-S(X1)-S-N-I(X2)-D(X3)-S；

CDR-VL3：I(X1)-Q-R-D(X2)-A-Y-P-L(X3)-T。

based on the CYFRA21-1 monoclonal antibody of example 1, mutations were made in the complementarity determining regions at sites relevant for antibody activity, wherein X1, X2, X3, X4 were all mutated sites. See table 1 below.

TABLE 1 mutant sites associated with antibody Activity

And (3) detecting the binding activity:

coating solution (PBS) diluted recombinant CYFRA21-1 protein (b)Self-production) to 1 mu g/ml, coating the micro-porous plate with 100 mu l of each hole at 4 ℃ overnight; the next day, washing with washing solution (PBS) for 2 times, and patting dry; blocking solution (20% BSA +80% PBS) was added, 120. Mu.l per well, 37 ℃,1h, patted dry; adding the diluted monoclonal antibody in the table 1 into the reaction kettle at the temperature of 37 ℃ for 30-60 min, wherein the concentration of the monoclonal antibody is 100 mu l/hole; washing with washing solution (PBS) for 5 times, and drying; adding goat anti-mouse IgG-HRP (goat anti-mouse IgG-HRP) with the concentration of 100 mu l per well at 37 ℃ for 30min; washing with washing solution for 5 times, and drying; adding color development liquid A (50 μ L/well containing 2.1g/L citric acid, 12.25g/L citric acid, 0.07g/L acetanilide and 0.5g/L carbamide peroxide) and adding color development liquid B (50 μ L/well containing 1.05g/L citric acid, 0.186g/L LEDTA.2Na, 0.45g/L TMB and 0.2ml/L concentrated HCl) for 10min; stop solution (50. Mu.l/well, containing 0.75 g/EDTA-2 Na and 10.2ml/L concentrated H) was added ₂ SO ₄ ) (ii) a OD readings were taken at 450nm (reference 630 nm) on the microplate reader. The results are shown in Table 2.

TABLE 2 Activity data for antibodies and mutants thereof

Antibody concentration (ng/ml)	100	50	25	12.5	6.25	0
							WT	1.733	1.154	0.678	0.417	0.241	0.080
Mutation 1	2.264	1.628	0.948	0.748	0.467	0.104
							Mutation 2	2.186	1.511	1.078	0.622	0.355	0.134
Mutation 3	2.148	1.576	1.043	0.851	0.402	0.112
							Mutation 4	2.197	1.643	1.194	0.657	0.349	0.084
Mutation 5	2.085	1.423	0.936	0.752	0.321	0.065
							Mutation 6	1.956	1.435	0.852	0.621	0.235	0.045
Mutation 7	0.321	0.048	-	-	-	-
							Mutation 8	0.254	0.056	-	-	-	-

As can be seen from the data in Table 2, WT and mutations 1-6 had better binding activity, while mutations 7-8 could not detect samples at antibody concentrations as low as 25ng/ml, indicating that the amino acid mutations at the mutation sites exemplified in Table 1 were unpredictable.

(2) Example 1 affinity assays for antibodies and mutants thereof

(a) Based on mutation 1, other sites were mutated, and the sequence of each mutation is shown in table 3 below.

TABLE 3 mutation sites related to antibody affinity

And (3) affinity detection:

using AMC sensors, purified antibodies (each of the mutant antibodies in table 3) were diluted with PBST at a 2-fold gradient starting at 50 μ g/ml and recombinant CYFRA21-1 protein was diluted with PBST at a gradient;

the operation flow is as follows: equilibration for 60s in buffer 1 (PBST), immobilized antibody for 300s in antibody solution, incubation for 180s in buffer 2 (PBST), binding for 420s in antigen solution, dissociation for 1200s in buffer 2, sensor regeneration with 10mM pH 1.69GLY solution and buffer 3, and data output. K is _D Represents the equilibrium dissociation constant, i.e., affinity; kon denotes the binding rate; kdis denotes the off-rate.

Table 4 affinity assay data

As can be seen from Table 4, K in mutation 1 and in mutations 1-1 to 1-57 _D The values are low, which indicates that the mutation mode of the mutation sites in Table 3 has no negative influence on the affinity of the antibody, and better affinity can be obtained after mutation.

(b) Based on WT, mutation is carried out on other sites, and the affinity of each mutant is detected, wherein the sequence of each mutation is shown in Table 5, and the corresponding affinity data is shown in Table 6.

TABLE 5 mutations with WT as backbone

TABLE 6 results of affinity assay of mutations with WT as backbone

As can be seen from the data in Table 6, WT and WT 1-1 to WT 1-7 all had better affinity, indicating that the way of mutation at the mutation site exemplified in Table 5 has little effect on the affinity of the antibody, and that better affinity can be obtained after mutation in this way.

(3) Evaluation of stability against naked antibody

Placing the antibodies in the table at 4 ℃ (refrigerator), -80 ℃ (refrigerator) and 37 ℃ (thermostat) for 21 days, taking samples at 7 days, 14 days and 21 days for state observation, and performing activity detection on the samples at 21 days, wherein the result shows that no obvious protein state change is seen in 21 days of placing the antibodies under three examination conditions, and the activity is more prone to decrease with the increase of the examination temperature, which indicates that the self-produced antibodies are stable. The following table shows the OD results of 21-day enzyme immunity activity tests of mutation 1.

TABLE 7 evaluation of antibody stability

Antibody concentration (ng/ml)	100	25	0
				Samples at 4 ℃ for 21 days	2.143	0.987	0.032
21 days samples at-80 deg.C	2.056	1.012	0.045
				21-day samples at 37 deg.C	2.199	1.043	0.078

As can be seen from Table 7, the antibodies of the examples of the present invention can still detect antigens after being stored for 21 days at different temperatures, which indicates that the antibodies provided by the examples of the present invention have better stability.

The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

SEQUENCE LISTING

<110> Dongguan City Peng Zhi Biotech Co., ltd

<120> binding protein for detecting CYFRA21-1 and detection method for CYFRA21-1

<160> 14

<170> PatentIn version 3.5

<210> 1

<211> 23

<212> PRT

<213> Artificial sequence

<400> 1

Asp Ile Gln Met Ile Gln Ser Pro Ser Ser Met Phe Ala Ser Leu Gly

1 5 10 15

Asp Arg Val Ser Leu Ser Cys

20

<210> 2

<211> 15

<212> PRT

<213> Artificial sequence

<400> 2

Trp Tyr Gln Gln Lys Pro Ala Gly Thr Ile Lys Leu Leu Ile Phe

1 5 10 15

<210> 3

<211> 32

<212> PRT

<213> Artificial sequence

<400> 3

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Ser Asp Tyr Ser

1 5 10 15

Leu Thr Ile Ser Ser Leu Glu Ser Glu Asp Phe Gly Asp Tyr Tyr Cys

20 25 30

<210> 4

<211> 11

<212> PRT

<213> Artificial sequence

<400> 4

Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg

1 5 10

<210> 5

<211> 25

<212> PRT

<213> Artificial sequence

<400> 5

Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Met Lys Leu Ser Cys Val Ala Ser

20 25

<210> 6

<211> 14

<212> PRT

<213> Artificial sequence

<400> 6

Trp Val Arg Gln Ser Pro Gly Lys Ala Leu Glu Trp Val Ala

1 5 10

<210> 7

<211> 30

<212> PRT

<213> Artificial sequence

<400> 7

Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr Leu Tyr Leu Gln

1 5 10 15

Met Asn Asn Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys

20 25 30

<210> 8

<211> 11

<212> PRT

<213> Artificial sequence

<400> 8

Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser

1 5 10

<210> 9

<211> 106

<212> PRT

<213> Artificial sequence

<400> 9

Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln

1 5 10 15

Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr

20 25 30

Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln

35 40 45

Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr

50 55 60

Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg

65 70 75 80

His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro

85 90 95

Ile Val Lys Ser Phe Asn Arg Asn Glu Cys

100 105

<210> 10

<211> 336

<212> PRT

<213> Artificial sequence

<400> 10

Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Cys Gly

1 5 10 15

Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr

20 25 30

Phe Pro Glu Ser Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser

35 40 45

Ser Val His Thr Phe Pro Ala Leu Leu Gln Ser Gly Leu Tyr Thr Met

50 55 60

Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser Gln Thr Val

65 70 75 80

Thr Cys Ser Val Ala His Pro Ala Ser Ser Thr Thr Val Asp Lys Lys

85 90 95

Leu Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Cys Pro Pro Cys

100 105 110

Lys Glu Cys His Lys Cys Pro Ala Pro Asn Leu Glu Gly Gly Pro Ser

115 120 125

Val Phe Ile Phe Pro Pro Asn Ile Lys Asp Val Leu Met Ile Ser Leu

130 135 140

Thr Pro Lys Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro

145 150 155 160

Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala

165 170 175

Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Ile Arg Val Val

180 185 190

Ser Thr Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe

195 200 205

Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ser Pro Ile Glu Arg Thr

210 215 220

Ile Ser Lys Ile Lys Gly Leu Val Arg Ala Pro Gln Val Tyr Ile Leu

225 230 235 240

Pro Pro Pro Ala Glu Gln Leu Ser Arg Lys Asp Val Ser Leu Thr Cys

245 250 255

Leu Val Val Gly Phe Asn Pro Gly Asp Ile Ser Val Glu Trp Thr Ser

260 265 270

Asn Gly His Thr Glu Glu Asn Tyr Lys Asp Thr Ala Pro Val Leu Asp

275 280 285

Ser Asp Gly Ser Tyr Phe Ile Tyr Ser Lys Leu Asn Met Lys Thr Ser

290 295 300

Lys Trp Glu Lys Thr Asp Ser Phe Ser Cys Asn Val Arg His Glu Gly

305 310 315 320

Leu Lys Asn Tyr Tyr Leu Lys Lys Thr Ile Ser Arg Ser Pro Gly Lys

325 330 335

<210> 11

<211> 108

<212> PRT

<213> Artificial sequence

<400> 11

Asp Ile Gln Met Ile Gln Ser Pro Ser Ser Met Phe Ala Ser Leu Gly

1 5 10 15

Asp Arg Val Ser Leu Ser Cys Arg Ala Ser Gln Asn Ile Arg Ser Asn

20 25 30

Ile Asp Trp Tyr Gln Gln Lys Pro Ala Gly Thr Ile Lys Leu Leu Ile

35 40 45

Phe Ser Ser Ser Asn Ile Asp Ser Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser

65 70 75 80

Glu Asp Phe Gly Asp Tyr Tyr Cys Ile Gln Arg Asp Ala Tyr Pro Leu

85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg

100 105

<210> 12

<211> 214

<212> PRT

<213> Artificial sequence

<400> 12

Asp Ile Gln Met Ile Gln Ser Pro Ser Ser Met Phe Ala Ser Leu Gly

1 5 10 15

Asp Arg Val Ser Leu Ser Cys Arg Ala Ser Gln Asn Ile Arg Ser Asn

20 25 30

Ile Asp Trp Tyr Gln Gln Lys Pro Ala Gly Thr Ile Lys Leu Leu Ile

35 40 45

Phe Ser Ser Ser Asn Ile Asp Ser Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser

65 70 75 80

Glu Asp Phe Gly Asp Tyr Tyr Cys Ile Gln Arg Asp Ala Tyr Pro Leu

85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala

100 105 110

Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly

115 120 125

Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile

130 135 140

Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu

145 150 155 160

Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser

165 170 175

Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr

180 185 190

Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser

195 200 205

Phe Asn Arg Asn Glu Cys

210

<210> 13

<211> 116

<212> PRT

<213> Artificial sequence

<400> 13

Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Met Lys Leu Ser Cys Val Ala Ser Gly Phe Ser Phe Ser Gln Tyr

20 25 30

Trp Met Asn Trp Val Arg Gln Ser Pro Gly Lys Ala Leu Glu Trp Val

35 40 45

Ala Glu Leu Thr Leu Lys Ser Asp Asn Tyr Ile Ala His Tyr Ala Glu

50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Gly Ile Tyr

85 90 95

Tyr Cys Thr His Phe Ala Met Glu Tyr Trp Gly Gln Gly Thr Ser Val

100 105 110

Thr Val Ser Ser

115

<210> 14

<211> 452

<212> PRT

<213> Artificial sequence

<400> 14

Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Met Lys Leu Ser Cys Val Ala Ser Gly Phe Ser Phe Ser Gln Tyr

20 25 30

Trp Met Asn Trp Val Arg Gln Ser Pro Gly Lys Ala Leu Glu Trp Val

35 40 45

Ala Glu Leu Thr Leu Lys Ser Asp Asn Tyr Ile Ala His Tyr Ala Glu

50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Gly Ile Tyr

85 90 95

Tyr Cys Thr His Phe Ala Met Glu Tyr Trp Gly Gln Gly Thr Ser Val

100 105 110

Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala

115 120 125

Pro Gly Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu

130 135 140

Val Lys Gly Tyr Phe Pro Glu Ser Val Thr Val Thr Trp Asn Ser Gly

145 150 155 160

Ser Leu Ser Ser Ser Val His Thr Phe Pro Ala Leu Leu Gln Ser Gly

165 170 175

Leu Tyr Thr Met Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro

180 185 190

Ser Gln Thr Val Thr Cys Ser Val Ala His Pro Ala Ser Ser Thr Thr

195 200 205

Val Asp Lys Lys Leu Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro

210 215 220

Cys Pro Pro Cys Lys Glu Cys His Lys Cys Pro Ala Pro Asn Leu Glu

225 230 235 240

Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Asn Ile Lys Asp Val Leu

245 250 255

Met Ile Ser Leu Thr Pro Lys Val Thr Cys Val Val Val Asp Val Ser

260 265 270

Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu

275 280 285

Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr

290 295 300

Ile Arg Val Val Ser Thr Leu Pro Ile Gln His Gln Asp Trp Met Ser

305 310 315 320

Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ser Pro

325 330 335

Ile Glu Arg Thr Ile Ser Lys Ile Lys Gly Leu Val Arg Ala Pro Gln

340 345 350

Val Tyr Ile Leu Pro Pro Pro Ala Glu Gln Leu Ser Arg Lys Asp Val

355 360 365

Ser Leu Thr Cys Leu Val Val Gly Phe Asn Pro Gly Asp Ile Ser Val

370 375 380

Glu Trp Thr Ser Asn Gly His Thr Glu Glu Asn Tyr Lys Asp Thr Ala

385 390 395 400

Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Ile Tyr Ser Lys Leu Asn

405 410 415

Met Lys Thr Ser Lys Trp Glu Lys Thr Asp Ser Phe Ser Cys Asn Val

420 425 430

Arg His Glu Gly Leu Lys Asn Tyr Tyr Leu Lys Lys Thr Ile Ser Arg

435 440 445

Ser Pro Gly Lys

450

Claims

1. A binding protein for detecting CYFRA21-1, wherein said binding protein comprises an antigen binding domain; the antigen binding domain includes the following 6 complementarity determining regions:

the amino acid sequence of the complementarity determining region CDR-VH1 is G-F-X1-F-S-X2-Y-W-M-N, wherein: x1 is T;

a complementarity determining region CDR-VH2 having an amino acid sequence of E-X1-T-L-K-S-X2-N-Y-X3-X4-H-Y-A-E-S-V-K-G, wherein: x1 is I;

Sub>A complementarity determining region CDR-VH3 having an amino acid sequence of T-X1-F-Sub>A-M-X2-Y, wherein: x2 is D;

a complementarity determining region CDR-VL1 having the amino acid sequence R-A-S-Q-X1-X2-R-X3-N-X4-D, wherein: x3 is G;

a complementarity determining region CDR-VL2 having an amino acid sequence S-X1-S-N-X2-X3-S, wherein: x1 is T;

a complementarity determining region CDR-VL3 having the amino acid sequence X1-Q-R-X2-A-Y-P-X3-T, wherein: x1 is L;

the mutation site of each complementarity determining region of the antigen binding domain is selected from any one of the following mutation combinations 1-58:

mutant combinations CDR-VH1 X2 CDR-VH2 X2/X3/X4 CDR-VH3 X1 CDR-VL1 X1/X2/X4 CDR-VL2 X2/X3 CDR-VL3 X2/X3 Mutant combination 1 Q D/I/A H N/I/I I/D D/L Combination of mutations 2 N D/I/I K D/I/I L/D D/I Combination of mutations 3 K D/I/L Q E/I/I I/N N/L Combination of mutations 4 N N/I/A R N/I/L L/N N/I Combination of mutations 5 K N/I/I K D/I/L L/D A/L Combination of mutations 6 Q N/I/L Q E/I/L L/N A/I Mutant combination 7 K D/V/A R N/L/I I/D N/I Combination of mutations 8 Q D/V/I H D/L/I I/N N/L Combination of mutations 9 N D/V/L Q E/L/I I/D A/I Combination of mutations 10 Q N/V/A R N/L/L L/N A/L Combination of mutations 11 N N/V/I H D/L/L I/N D/I Mutant combination 12 K N/V/L K E/L/L L/N D/L Mutant combinations 13 N D/A/A R N/L/I L/D A/L Combination of mutations 14 K D/A/I H N/L/L I/D A/I Combination of mutations 15 Q D/A/L K D/L/I L/N D/L Mutant combinations 16 K N/A/A Q D/L/L I/N D/I Mutant combinations 17 Q N/A/I H E/L/I I/D N/L Combination of mutations 18 N N/A/L H E/L/L L/D N/I Combination of mutations 19 Q N/A/L K N/L/L I/N D/L Combination of mutations 20 Q N/A/I K D/L/L L/N D/I Combination of mutations 21 K N/A/A Q E/L/L L/D N/L Mutant combination 22 Q D/A/L Q N/L/I L/N N/I Combination of mutations 23 Q D/A/I R D/L/I I/D A/L Mutant combinations 24 N D/A/A R E/L/I I/N A/I Mutant combinations 25 N N/V/L K N/I/L I/D N/I Mutant combinations 26 K N/V/I K D/I/L L/N N/L Mutant combinations 27 N N/V/A Q E/I/L I/N A/I Mutant combination 28 Q D/V/L Q N/I/I L/N A/L Mutant combinations 29 N D/V/I R D/I/I I/D D/I Combination of mutations 30 N D/V/A R E/I/I L/D D/L Combination of mutations 31 K N/I/L H N/L/I I/D A/L Mutant combinations 32 N N/I/I H N/L/L L/D A/I Mutant combinations 33 K N/I/A Q D/L/I I/N D/L Mutant combinations 34 N D/I/L Q D/L/L L/N D/I Combination of mutations 35 Q D/I/I R E/L/I L/D N/L Combination of mutations 36 Q D/I/A R E/L/L L/N N/I Mutant combinations 37 N N/I/A H N/L/L L/D D/L Combination of mutations 38 N N/I/I H D/L/L I/N D/I Mutant combinations 39 Q N/I/L K E/L/L I/D N/L Combination of mutations 40 N D/A/L K N/L/I L/N N/I Mutant combination 41 Q D/A/I H D/L/I L/D A/L Combination of mutations 42 Q D/A/A K E/L/I I/D A/I Combination of mutations 43 K N/V/L Q N/I/L I/N N/I Mutant combinations 44 N N/V/I R D/I/L L/N N/L Combination of mutations 45 N N/V/A K E/I/L I/D A/I Mutant combinations 46 N D/V/L Q N/I/I L/D A/L Mutant combinations 47 Q D/V/I R D/I/I I/N D/I Mutant combinations 48 Q D/V/A H E/I/I L/N D/L Mutant combinations 49 K N/I/L Q N/L/I L/D A/L Mutant combinations 50 K N/I/I R N/L/L L/N A/I Mutant combinations 51 Q N/I/A H D/L/I I/D D/L Mutant combinations 52 K D/I/L K D/L/L I/N D/I Mutant combination 53 K D/I/I R E/L/I L/D N/L Mutant combinations 54 N D/I/A H E/L/L L/N N/I Mutant combinations 55 Q D/I/A K N/I/I L/N D/L Mutant combinations 56 N D/V/A Q D/I/I L/D D/I Mutant combinations 57 N D/A/A Q E/I/I L/D N/L Mutant combinations 58 N N/I/A R N/I/L I/N N/I

。

2. A binding protein for detecting CYFRA21-1, wherein said binding protein comprises an antigen binding domain; the antigen binding domain includes the following 6 complementarity determining regions:

the amino acid sequence of the complementarity determining region CDR-VH1 is G-F-X1-F-S-X2-Y-W-M-N;

a complementarity determining region CDR-VH2, the amino acid sequence of which is E-X1-T-L-K-S-X2-N-Y-X3-X4-H-Y-A-E-S-V-K-G;

Sub>A complementarity determining region CDR-VH3, the amino acid sequence of which is T-X1-F-A-M-X2-Y;

a complementary determining region CDR-VL1, the amino acid sequence of which is R-A-S-Q-X1-X2-R-X3-N-X4-D;

a complementarity determining region CDR-VL2, the amino acid sequence of which is S-X1-S-N-X2-X3-S;

a complementarity determining region CDR-VL3, the amino acid sequence of which is X1-Q-R-X2-A-Y-P-X3-T;

in the complementarity determining region CDR-VH1, X1 is S;

in the complementarity determining region CDR-VH2, X1 is L;

in the CDR-VH3, X2 is E;

in the complementarity determining region CDR-VL1, X3 is S;

in the complementarity determining region CDR-VL2, X1 is S;

in the complementarity determining region CDR-VL3, X1 is I;

the mutation site of each complementarity determining region of the antigen binding domain is selected from any one of the following mutation combinations 59-66:

combination of mutations CDR-VH1 X2 CDR-VH2 X2/X3/X4 CDR-VH3 X1 CDR-VL1 X1/X2/X4 CDR-VL2 X2/X3 CDR-VL3 X2/X3 Mutant combination 59 Q D/I/A H N/I/I I/D D/L Mutant combinations 60 N N/V/I H E/I/L L/N N/L Combination of mutations61 K D/L/A H E/I/L I/N A/L Mutant combinations 62 K N/I/A K N/L/L L/N A/L Mutant combinations 63 Q N/V/A Q D/L/I I/D A/I Mutant combinations 64 K D/I/A R N/L/I I/D N/L Mutant combinations 65 N N/I/L R D/I/L L/D D/I Mutant combinations 66 K D/L/A H E/L/L I/N A/L

。

3. The binding protein of any one of claims 1-2, wherein said binding protein is an antibody or a functional fragment thereof.

4. The binding protein of claim 3, wherein said binding protein is selected from any one of F (ab ') 2, fab', fab, fv, scFv, and diabody.

5. The binding protein according to any one of claims 1-2, wherein said binding protein comprises the light chain framework regions FR-L1, FR-L2, FR-L3 and FR-L4 as shown in the sequence SEQ ID NOs 1-4, and/or the heavy chain framework regions FR-H1, FR-H2, FR-H3 and FR-H4 as shown in the sequence SEQ ID NOs 5-8.

6. The binding protein according to any one of claims 1-2, wherein said binding protein further comprises an antibody constant region.

7. The binding protein of claim 6, wherein the antibody constant region is selected from the constant regions of any one of IgG1, igG2, igG3, igG4, igA, igM, igE, and IgD.

8. The binding protein of claim 6, wherein said antibody constant region is of a species of bovine, equine, porcine, ovine, caprine, rat, mouse, canine, feline, rabbit, donkey, deer, mink, chicken, duck, goose, or human origin.

9. The binding protein according to claim 8, wherein the bovine is selected from the group consisting of dairy cattle; alternatively, the chicken is selected from turkey or turkey.

10. The binding protein of claim 6, wherein said antibody constant region is derived from a mouse.

11. The binding protein of claim 6, wherein said antibody constant region light chain constant region sequence is set forth in SEQ ID NO. 9 and said antibody constant region heavy chain constant region sequence is set forth in SEQ ID NO. 10.

12. Use of a binding protein according to any one of claims 1 to 11in the preparation of a reagent for the detection of CYFRA21-1 antigen.

13. Use of a binding protein according to any one of claims 1 to 11in the preparation of a kit for detecting CYFRA21-1 in a test sample.

14. The use according to claim 13, wherein the kit is for:

mixing the binding protein of any one of claims 1-11 with a sample to be tested;

the CYFRA21-1 detection method is realized by a precipitation reaction or the CYFRA21-1 detection is realized by marking an indicator showing signal intensity.

15. The use according to claim 14, wherein the CYFRA21-1 detection is achieved by a precipitation reaction by any one or more methods selected from the group consisting of: one-way immunodiffusion assay, two-way immunodiffusion assay, immunoturbidimetry, immunoelectrophoresis, and immunoblotting.

16. Use according to claim 15, wherein said immunoelectrophoresis comprises convection immunoelectrophoresis.

17. The use according to claim 14, wherein the method for detecting CYFRA21-1 by marking an indicator showing signal intensity is selected from any one or more of the following methods: immunofluorescence, radioimmunoassay, enzyme linked immunoassay, and chemiluminescent immunoassay.

18. The use of claim 14, wherein the indicator is selected from any one of a fluorescent dye, a radioisotope, an enzyme that catalyzes the color development of a substrate, and a chemiluminescent reagent.

19. A vector comprising a nucleic acid encoding the binding protein according to any one of claims 1 to 11.

20. A host cell comprising the vector of claim 19.

21. A method of producing the binding protein of any one of claims 1 to 11, comprising:

culturing the host cell of claim 20, and isolating and purifying the binding protein from the culture medium or from the cultured host cell.